. home.aspx



AZs asthma and diabetes drugs get label boosts in EU

July 01, 2019 / Richard Staines

Two of AstraZenecas most important drugs have received a boost, after European regulators backed a pen allowing people to inject themselves with respiratory drug Fasenra, and agreed that cardiovascular benefits data could be added to the label of diabetes drug Forxiga. The European Medicines Agency’s CHMP regulatory committee gave a positive opinion to add a self-administration option for asthma injection Fasenra (benralizumab), based on a new delivery method as a pre-filled, single-use auto-injector. Fasenra already has a convenience advantage over two rivals from the same class, GlaxoSmithKline’s Nucala (mepolizumab) and Teva’s rival Cinqaero (reslizumab) as it is given every eight weeks, after the first three doses administered that are four weeks apart. Both Nucala and Cinqaero, which are also interleukin-5 inhibitors, are injected every four weeks. Following the CHMP’s nod, the drug’s label can be changed without need for confirmation from the Europea...